Southern California Research Center

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)12 trials
• Liver cirrhosis7 trials
• Primary biliary cholangitis7 trials
• Crohn's disease2 trials
• Ulcerative colitis2 trials
• Liver and biliary tract cancer1 trial

Phase

• Phase 212 trials
• Phase 39 trials
• Phase 12 trials
• Phase 1/21 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed9 trials
• Active, not recruiting8 trials
• Recruiting7 trials
• Terminated2 trials
• Not yet recruiting1 trial

Lead sponsor

• Boehringer Ingelheim5 trials
• Janssen Research & Development, LLC4 trials
• Ipsen3 trials
• Madrigal Pharmaceuticals, Inc.2 trials
• Regeneron Pharmaceuticals2 trials
• and 11 more

Running trials

• Recruiting

  Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

  NCT07848191· Phase 4· Madrigal Pharmaceuticals, Inc.· Source

  Contact: Tom Hare

• Recruiting

  A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

  NCT07527910· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

  NCT07325526· Phase 2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

  NCT06447168· Ipsen· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

  Contact: Ipsen Clinical Study Enquiries

• Active, not recruiting

  A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

  NCT05490888· Phase 1· PharmaIN· Source

  Contact: Kasey Seyer

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

  NCT04194775· Phase 3· CStone Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)5 recruiting
• Liver cirrhosis3 recruiting
• Crohn's disease1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Completed

  A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

  NCT06675929· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Intercept Pharmaceuticals· Source

• Completed

  Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

  NCT06054815· Phase 2· NeuroBo Pharmaceuticals Inc.· Source

• Terminated

  A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

  NCT07052682· Phase 1· Takeda· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Escient Pharmaceuticals, Inc· Source

• Completed

  Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

  NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Completed

  Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

  NCT03451292· Phase 3· Grifols Therapeutics LLC· Source